Mariko Harada-Sheba (Japan)

National Cerebral and Cardiovascular Center Research Institute Molecular Pathogenesis
Mariko Harada-Shiba received her MD from Shiga University of Medical Science in 1984 and PhD in 1988. She then held a Post-Doctoral and Research Associate position in the Department of Etiology and Pathophysiology (Dr. Akira Yamamoto’s lab) in National Cardiovascular Center and studied LDL apheresis therapy in homozygous and heterozygous FH patients. Since then, she has been involved in the project of LDL apheresis treatment in FH and PAD. In 1996, she joined the Department of Biochemistry (Dr. Richard Hanson’s lab) in Case Western Reserve University in USA. She has been devoted to clinical and basic FH studies. She has been a chair of Japanese FH guideline committee and was involved in the establishment of Japanese guideline. She also has been involved in the development of novel therapeutic strategy using antisense drugs. She had been the Director of the Department of Molecular Innovation in Lipidology in National Cerebral and Cardiovascular Center Research Institute. Now she is a Council member of Science Council of Japan, a Board Director of Japan Apheresis Society and Japan Atherosclerosis Society.